| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8739608 | Journal of Autoimmunity | 2017 | 13 Pages |
Abstract
Several clinical protocol will be here discussed and summarised to show the feasibility of these passive transfer approaches, and also their very limited toxicity. Finally, preliminary indications on clinical efficacy, particularly in hematologic malignancies and against minimal residual disease, will be shown and discussed, as well as the future perspectives to optimize this adoptive passive cell immunotherapy strategy by gene transfer technology or bispecific monoclonal antibodies addition.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
M. Introna,